References

Global, regional, and national trends and burden of opioid use disorder in individuals aged 15 years and above: 1990 to 2021 and projections to 2040

10.1017/s2045796025100085 · 2025 · External reference

Unresolved reference

External reference

Fentanyl and other opioid use disorders: Treatment and research needs

10.1176/appi.ajp.20230273 · 2023 · External reference

Buprenorphine/Naloxone vs methadone for the treatment of opioid use disorder

10.1001/jama.2024.16954 · 2024 · External reference

Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: Outcomes during and after intervention

10.1007/s11606-017-3993-2 · 2017 · External reference

Efficacy of maintenance treatment with naltrexone for opioid dependence: A meta-analytical review

10.1111/j.1360-0443.2006.01369.x · 2006 · External reference

The opioid crisis and HIV in the USA: Deadly synergies

10.1016/s0140-6736(21)00391-3 · 2021 · External reference

Barriers and facilitators to the use of medications for opioid use disorder: A rapid review

10.1007/s11606-020-06257-4 · 2020 · External reference

Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population

10.1016/j.jsat.2017.07.001 · 2018 · External reference

Neurobiology of addiction: A neurocircuitry analysis

10.1016/s2215-0366(16)00104-8 · 2016 · External reference

Dysfunction of the prefrontal cortex in addiction: Neuroimaging findings and clinical implications

10.1038/nrn3119 · 2011 · External reference

Rapid neuroplasticity changes and response to intravenous ketamine: A randomized controlled trial in treatment-resistant depression

10.1038/s41398-023-02451-0 · 2023 · External reference

Ketamine in treating opioid use disorder and opioid withdrawal: A scoping review

10.3389/fpsyt.2025.1552084 · 2025 · External reference

Attenuation of antidepressant effects of ketamine by opioid receptor antagonism

10.1176/appi.ajp.2018.18020138 · 2018 · External reference

Ketamine and major ketamine metabolites function as allosteric modulators of opioid receptors

10.1124/molpharm.124.000947 · 2024 · External reference

Structural basis of opioid receptor activation by PCP and ketamine

10.1038/s41594-026-01839-y · 2026 · External reference

Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans

10.1002/jps.2600710516 · 1982 · External reference

Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers

10.1002/bdd.336 · 2003 · External reference

Therapeutic protocols using ketamine and esketamine for depressive disorders: A systematic review

10.1080/02791072.2023.2248989 · 2024 · External reference

Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up

10.1016/s0740-5472(02)00275-1 · 2002 · External reference

Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence

10.1080/02791072.2007.10399860 · 2007 · External reference

Effects of ketamine on precipitated opiate withdrawal

2006 · External reference

Adjunctive ketamine vs. buprenorphine in co-occurring major depressive disorder and opioid use disorder: A randomized, double-blind clinical trial assessing anxiety symptom severity and craving intensity

10.1186/s13063-025-08836-4 · 2025 · External reference

Ketamine-assisted mindfulness-oriented recovery enhancement for opioid use disorder: A randomized controlled trial

10.1038/s44220-026-00625-5 · 2026 · External reference

Long-term safety of ketamine and esketamine in treatment of depression

10.1080/14740338.2022.2066651 · 2022 · External reference

Chronic administration of ketamine induces cognitive deterioration by restraining synaptic signaling

10.1038/s41380-020-0793-6 · 2021 · External reference

Unresolved reference

External reference

Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression

10.1080/00952990.2025.2541212 · 2025 · External reference

Cannabis addiction and the brain: A review

10.1007/s11481-018-9782-9 · 2018 · External reference

The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone

10.1016/j.drugalcdep.2015.05.013 · 2015 · External reference

Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans

10.1016/j.drugalcdep.2016.05.002 · 2016 · External reference

THC and CBD: Similarities and differences between siblings

10.1016/j.neuron.2022.12.022 · 2023 · External reference

Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor

10.1111/bph.13250 · 2015 · External reference

Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors

10.1007/s00210-006-0033-x · 2006 · External reference

Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial

10.1176/appi.ajp.2019.18101191 · 2019 · External reference

Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial

10.3389/fpsyt.2023.1155984 · 2023 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Exploring the therapeutic potential of psychedelics in treating substance use disorders

10.1038/s41380-025-03168-w · 2025 · External reference

Unresolved reference

External reference

The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies

10.1016/j.psychres.2025.116446 · 2025 · External reference

Treatment of acute opioid withdrawal with ibogaine

10.1080/105504999305848 · 1999 · External reference

Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes

10.1080/00952990.2017.1320802 · 2018 · External reference

Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes

10.3389/fphar.2018.00529 · 2018 · External reference

A non-hallucinogenic psychedelic analogue with therapeutic potential

10.1038/s41586-020-3008-z · 2021 · External reference

Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models

10.1038/s41467-024-51856-y · 2024 · External reference

Accelerated recovery using magnesium ibogaine: Characterizing the subjective experience of its rapid healing from neuropsychiatric disorders

10.1038/s44184-026-00185-7 · 2026 · External reference

Residential psychedelic (LSD) therapy for the narcotic addict: A controlled study

10.1001/archpsyc.1973.01750360040005 · 1973 · External reference

Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada

10.2174/15733998113099990003 · 2013 · External reference

Psilocybin for opioid use disorder in two adults stabilized on buprenorphine: A technical report on study modifications and preliminary findings

10.1089/psymed.2023.0012 · 2023 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Serotonin toxicity of serotonergic psychedelics

10.1007/s00213-021-05876-x · 2022 · External reference

Differential drug use patterns among sexually abused adolescent girls in treatment for chemical dependency

10.3109/10826088909081832 · 1989 · External reference

The incretin system in healthy humans: The role of GIP and GLP-1

10.1016/j.metabol.2019.04.014 · 2019 · External reference

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from Guinea pig pancreas

10.1016/s0021-9258(18)42531-8 · 1992 · External reference

The central GLP-1: Implications for food and drug reward

10.3389/fnins.2013.00181 · 2013 · External reference

Mechanisms of GLP-1 in modulating craving and addiction: Neurobiological and translational insights

10.3390/medsci13030136 · 2025 · External reference

Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats

10.1111/adb.13117 · 2022 · External reference

Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats

10.1016/j.brainresbull.2022.08.022 · 2022 · External reference

The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis

10.1111/add.16679 · 2025 · External reference

Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder

10.1001/jamanetworkopen.2024.35247 · 2024 · External reference

Association between GLP-1 receptor agonist use and substance use disorders among individuals with type 2 diabetes or obesity: A nested case-control study in the All of Us research program

10.3389/fpsyt.2026.1766770 · 2026 · External reference

Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: Cohort study

10.1136/bmj-2025-086886 · 2026 · External reference

Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review

10.1016/j.clnu.2025.106571 · 2026 · External reference

The science of safety: Adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications

10.1172/jci194740 · 2026 · External reference

Mapping the effectiveness and risks of GLP-1 receptor agonists

10.1038/s41591-024-03412-w · 2025 · External reference

The role of withdrawal in mesocorticolimbic drug cue reactivity in opioid use disorder

10.1111/adb.12977 · 2021 · External reference

Subanesthetic ketamine decreases the incentive-motivational value of reward-related cues

10.1177/0269881116667709 · 2017 · External reference

Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics

10.1016/j.tips.2021.08.003 · 2021 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach

10.1159/000069738 · 2003 · External reference